Geron (GERN) Income from Continuing Operations (2010 - 2026)
Geron (GERN) posted Income from Continuing Operations of 3568000.0 for Q1 2026, up 87.61% sequentially from 28792000.0 in Q4 2025, and up 81.94% YoY from 1961129.12 in Q1 2025.
Geron (GERN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Geron has reported Income from Continuing Operations for 17 years, with the latest figure at 3568000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 81.94% year-over-year to 3568000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66941000.0 (up 51.16% YoY) and the FY2025 annual result came in at 495118000.0, up 15.23% from the prior year.
- Income from Continuing Operations advanced to 3568000.0 in Q1 2026 per GERN's latest filing, from 28792000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3568000.0 in Q1 2026 and troughed at 67320000.0 in Q2 2024.
- A 5-year average of 34350411.76 and a median of 30693000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations tumbled 68.39% in 2023, then soared 81.94% in 2026.
- Over 5 years, Income from Continuing Operations stood at 40993000.0 in 2022, then decreased by 23.73% to 50719000.0 in 2023, then surged by 53.48% to 23597000.0 in 2024, then retreated by 22.02% to 28792000.0 in 2025, then soared by 87.61% to 3568000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3568000.0, 28792000.0, and 18267000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -16.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.67 Mn |
| Mar 31, 2026 | -3.57 Mn |
| Dec 31, 2025 | -28.79 Mn |
| Sep 30, 2025 | -18.27 Mn |
| Jun 30, 2025 | -16.31 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -23.60 Mn |
| Sep 30, 2024 | -26.38 Mn |
| Jun 30, 2024 | -67.32 Mn |
| Mar 31, 2024 | -55.33 Mn |
| Dec 31, 2023 | -50.72 Mn |
| Sep 30, 2023 | -44.71 Mn |
| Jun 30, 2023 | -49.22 Mn |
| Mar 31, 2023 | -38.16 Mn |
| Dec 31, 2022 | -40.99 Mn |
| Sep 30, 2022 | -40.91 Mn |
| Jun 30, 2022 | -29.23 Mn |
| Mar 31, 2022 | -30.69 Mn |
| Dec 31, 2021 | -30.98 Mn |
| Sep 30, 2021 | -26.62 Mn |